Fetuin-A and Incident Diabetes Mellitus in Older Persons
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
CONTEXT: Fetuin-A is a hepatic secretory protein that binds the insulin receptor and inhibits insulin action in vitro. In prior cross-sectional studies in humans, higher fetuin-A levels were associated with insulin resistance. However, the longitudinal association of fetuin-A with incident type 2 diabetes mellitus is unknown. OBJECTIVE: To determine whether fetuin-A levels are associated with incident diabetes in older persons. DESIGN, SETTING, AND PARTICIPANTS: Observational study among 3075 well-functioning persons aged 70 to 79 years. In this case-cohort study, we retrospectively measured fetuin-A levels in baseline serum among 406 randomly selected participants without prevalent diabetes, and all participants who developed incident diabetes mellitus during a 6-year follow-up (to August 31, 2005). MAIN OUTCOME MEASURE: Incident diabetes mellitus. RESULTS: Incident diabetes developed in 135 participants (10.1 cases/1000 person-years). Participants with fetuin-A levels within the highest tertile (> 0.97 g/L) had an increased risk of incident diabetes (13.3 cases/1000 person-years) compared with participants in the lowest tertile (< or = 0.76 g/L) (6.5 cases/1000 person-years) in models adjusted for age, sex, race, waist circumference, body weight, physical activity, blood pressure level, fasting glucose level, high-density lipoprotein cholesterol concentration, triglyceride concentration, and C-reactive protein level (adjusted hazard ratio, 2.41; 95% confidence interval, 1.28-4.53; P = .007). The association was not affected by adipocytokine levels but was moderately attenuated by adjustment for visceral adiposity (adjusted hazard ratio of highest vs lowest tertile 1.72; 95% confidence interval, 0.98-3.05; P = .06). CONCLUSION: Among well-functioning older persons, serum fetuin-A is associated with incident diabetes, independent of other markers of insulin resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Levey, A. S., Bosch, J. P., Lewis, J. B., Greene, T., Rogers, N., Roth, D., & for the Modification of Diet in Renal Disease Study Group* (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00002 · Cited by 15,079
(1998) · PsycEXTRA Dataset · doi:10.1037/e565682010-001 · Cited by 9,472
Prevalence and Trends in Obesity Among US Adults, 1999-2008
Flegal, K. M. (2010) · JAMA · doi:10.1001/jama.2009.2014 · Cited by 7,580
Global Burden of Diabetes, 1995–2025: Prevalence, numerical estimates, and projections
King, H., Aubert, R. E., & Herman, W. H. (1998) · Diabetes Care · doi:10.2337/diacare.21.9.1414 · Cited by 6,311
Prevalence and trends in obesity among US adults, 1999–2000
Flegal, K. M. (2002) · JAMA · doi:10.1001/jama.288.14.1723 · Cited by 6,190
Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels
Saxena, R., Voight, B. F., Lyssenko, V., Burtt, N. P., de Bakker, P. I. W., Chen, H., Roix, J. J., Kathiresan, S., Hirschhorn, J. N., Daly, M. J., et al. (2007) · Science · doi:10.1126/science.1142358 · Cited by 2,843 · cited 1×
“Leptin, median (IQR), ng/mLb 10 (5-18) 10 (4-22) 11 (5-22) .”
(1998) · PubMed · Cited by 2,737
The Continuing Epidemics of Obesity and Diabetes in the United States
Mokdad, A. H. (2001) · JAMA · doi:10.1001/jama.286.10.1195 · Cited by 2,730
The Robust Inference for the Cox Proportional Hazards Model
Lin, D. Y., & Wei, L. J. (1989) · Journal of the American Statistical Association · doi:10.1080/01621459.1989.10478874 · Cited by 2,695
A case-cohort design for epidemiologic cohort studies and disease prevention trials
PRENTICE, R. L. (1986) · Biometrika · doi:10.1093/biomet/73.1.1 · Cited by 1,439
Cited by
Schwenzer, N. F., Springer, F., Schraml, C., Stefan, N., Machann, J., & Schick, F. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.05.023 · Cited by 749
Causes and Metabolic Consequences of Fatty Liver
Stefan, N., Kantartzis, K., & Häring, H.-U. (2008) · Endocrine Reviews · doi:10.1210/er.2008-0009 · Cited by 532
Bennett, J. M., Reeves, G., Billman, G. E., & Sturmberg, J. P. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00316 · Cited by 531
The role of hepatokines in metabolism
Stefan, N., & Häring, H.-U. (2013) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.258 · Cited by 500
The impact of insulin resistance on the kidney and vasculature
Artunc, F., Schleicher, E., Weigert, C., Fritsche, A., Stefan, N., & Häring, H.-U. (2016) · Nature Reviews Nephrology · doi:10.1038/nrneph.2016.145 · Cited by 462
Parker, B. D., Schurgers, L. J., Brandenburg, V. M., Christenson, R. H., Vermeer, C., Ketteler, M., Shlipak, M. G., Whooley, M. A., & Ix, J. H. (2010) · Annals of Internal Medicine · doi:10.7326/0003-4819-152-10-201005180-00004 · Cited by 457
Self-citationIx, J. H., & Sharma, K. (2010) · Journal of the American Society of Nephrology · doi:10.1681/asn.2009080820 · Cited by 348
Self-citationPlasma Fetuin-A Levels and the Risk of Myocardial Infarction and Ischemic Stroke
Weikert, C., Stefan, N., Schulze, M. B., Pischon, T., Berger, K., Joost, H.-G., Häring, H.-U., Boeing, H., & Fritsche, A. (2008) · Circulation · doi:10.1161/circulationaha.108.814418 · Cited by 310
Kantartzis, K., Peter, A., Machicao, F., Machann, J., Wagner, S., Königsrainer, I., Königsrainer, A., Schick, F., Fritsche, A., Häring, H.-U., et al. (2009) · Diabetes · doi:10.2337/db09-0279 · Cited by 303
The role of hepatokines in NAFLD
Stefan, N., Schick, F., Birkenfeld, A. L., Häring, H.-U., & White, M. F. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.01.006 · Cited by 282
Metabolic adaptation in obesity and type ii diabetes: myokines, adipokines and hepatokines
Oh, K.-J., Lee, D., Kim, W., Han, B., Lee, S., & Bae, K.-H. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms18010008 · Cited by 210
“Circulating fetuin-A is also related to hepatic steatosis, impaired glucose tolerance, and insulin resistance [276,277].”
BackgroundDasgupta, S., Bhattacharya, S., Biswas, A., Majumdar, S. S., Mukhopadhyay, S., Ray, S., & Bhattacharya, S. (2010) · Biochemical Journal · doi:10.1042/bj20100330 · Cited by 168
Insulin Resistance in Patients with Chronic Kidney Disease
Liao, M.-T., Sung, C.-C., Hung, K.-C., Wu, C.-C., Lo, L., & Lu, K.-C. (2012) · Journal of Biomedicine and Biotechnology · doi:10.1155/2012/691369 · Cited by 165
“serum fetuin-A was associated with IR [65] and its comorbidities, such as MetS [66] and type 2 DM [67, 68].”
BackgroundFetuin-A: A novel link between obesity and related complications
Trepanowski, J. F., Mey, J., & Varady, K. A. (2015) · International Journal of Obesity · doi:10.1038/ijo.2014.203 · Cited by 161
Implication of hepatokines in metabolic disorders and cardiovascular diseases
Jung, T. W., Yoo, H. J., & Choi, K. M. (2016) · BBA Clinical · doi:10.1016/j.bbacli.2016.03.002 · Cited by 71
“for the incidence of T2DM after adjusting for risk factors [29,30].”
BackgroundFetuin-A and change in body composition in older persons
Ix, J. H., Wassel, C. L., Chertow, G. M., Koster, A., Johnson, K. C., Tylavsky, F. A., Cauley, J. A., Cummings, S. R., Harris, T. B., Shlipak, M. G., et al. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0916 · Cited by 51
Self-citationTelgenkamp, I., Kusters, Y. H. A. M., Schalkwijk, C. G., Houben, A. J. H. M., Kooi, M. E., Lindeboom, L., Bons, J. A. P., Schaper, N. C., Joris, P. J., Plat, J., et al. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-02378 · Cited by 18
Metadata
- Authors
- Ix, J. H.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2008-07-09
- Volume
- 300
- Issue
- 2
- Pages
- 182
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2089151518
- Cited by
- 267
- References
- 48
- FWCI
- 12.92
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.